NASDAQ:STAA - STAAR Surgical Stock Price, Price Target & More

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) issued its earnings results on Wednesday, May, 2nd. The medical instruments supplier reported $0.04 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.08. The medical instruments supplier earned $27.09 million during the quarter, compared to the consensus estimate of $23 million. STAAR Surgical had a return on equity of 6.80% and a net margin of 0.66%. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for STAAR Surgical.

4 equities research analysts have issued 1-year target prices for STAAR Surgical's shares. Their predictions range from $21.00 to $32.00. On average, they expect STAAR Surgical's stock price to reach $24.6667 in the next twelve months. This suggests that the stock has a possible downside of 27.2%. View Analyst Ratings for STAAR Surgical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to STAAR Surgical include Integra Lifesciences (IART), Canopy Growth (CGC), DiaSorin (DSRLF), United Therapeutics (UTHR), FibroGen (FGEN), Aurora Cannabis (ACB), Envision Healthcare (EVHC), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Masimo (MASI), STADA Arzneimittel (SAZ), Agios Pharmaceuticals (AGIO), Chemed (CHE), Insulet (PODD) and Haemonetics (HAE).

Press coverage about STAA stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. STAAR Surgical earned a news impact score of 0.08 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

STAAR Surgical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (2.78%), Columbia Partners L L C Investment Management (0.27%), Fred Alger Management Inc. (0.08%) and Creative Planning (0.04%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday and Samuel J Gesten. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was acquired by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management, Baillie Gifford & Co., Fred Alger Management Inc. and Creative Planning. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $33.90.

STAAR Surgical has a market capitalization of $1.41 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]